NCT05768386
Hemophilia A, Hemophilia a
The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.
The BMN 270 clinical development program consists of multiple interventional studies designed to assess the safety and efficacy of a single infusion of BMN 270 for at least 5 years post-infusion. This long-term follow-up study is needed to help further understand the long-term safety of BMN 270 beyond 5 years and to assess the durability of efficacy.
Male
From 18 Years
No
Observational
172
2023-01-01
2024-04-24
Los Angeles, California, United States
Sacramento, California, United States
Shandon, California, United States
Aurora, Colorado, United States
Tampa, Florida, United States
Ann Arbor, Michigan, United States
Pittsburgh, Pennsylvania, United States
Cambridge, , United Kingdom
London, , United Kingdom
London, , United Kingdom
London, , United Kingdom
London, , United Kingdom
Southampton, , United Kingdom
*required fields
"*" indicates required fields